Extended Data Table 2 A. Any-Grade AEs Occurring in ≥20% of Patients by Dosing Cohort, Part 1; B. Grade 3-4 AEs Occurring in ≥5% of Patients by Dosing Cohort, Part 1

From: Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

  1. AE, adverse event.